Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

(2021) Kristian Reich et al.   LANCET

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials

(2020) E.L. Simpson et al.   BRITISH JOURNAL OF DERMATOLOGY

Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life

(2020) Sascha Gerdes et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

(2020) Eric Simpson et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib

(2020) Sandra Ferreira et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study

(2020) J.I. Silverberg et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

(2020) Eric L Simpson et al.   LANCET

Atopic dermatitis

(2020) Sinéad M Langan et al.   LANCET

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis

(2020) Jonathan I. Silverberg et al.   JAMA Dermatology

JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data

(2020) Robert Harrington et al.   Journal of Inflammation Research

Process utilities for topical treatment in atopic dermatitis

(2019) Jenny Retzler et al.   QUALITY OF LIFE RESEARCH

Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial

(2019) Emma Guttman-Yassky et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials

(2019) Ahmed Nader et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Atopic dermatitis epidemiology and unmet need in the United Kingdom

(2019) Michael J. Cork et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis

(2019) Melinda J. Gooderham et al.   JAMA Dermatology

Targeting the Janus Kinase Family in Autoimmune Skin Diseases

(2019) Michael D. Howell et al.   Frontiers in Immunology

Atopic dermatitis in diverse racial and ethnic groups-Variations in epidemiology, genetics, clinical presentation and treatment

(2018) Bridget P. Kaufman et al.   EXPERIMENTAL DERMATOLOGY

Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study

(2018) Emma Guttman-Yassky et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Atopic dermatitis

(2018) Stephan Weidinger et al.   Nature Reviews Disease Primers

Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis

(2018) Amalie Thorsti Møller Rønnstad et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Autoimmune diseases in adults with atopic dermatitis

(2017) Yuki M.F. Andersen et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

JAK inhibitors in dermatology: The promise of a new drug class

(2017) William Damsky et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Janus kinase inhibitors in dermatology: A systematic review

(2017) Rony Shreberk-Hassidim et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes

(2016) Jochen Schmitt et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

(2016) Eric L. Simpson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis

(2015) Lavinia Paternoster et al.   NATURE GENETICS